Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis

Table 3 Second-line treatment, stratified by first-line treatment n (%)

	First-line treatment							Patients withsecond-line treatment
	SSA	CC	TT	SSA + CC	SSA + TT	TT + CC	IF
n	128	33	14	5	7	1	1	189
	67.7%	17.5%	7.4%	2.6%	3.7%	0.5%	0.5%	100.0%
Second-line treatment
SSA + TT	51 (39.8)	4 (12.1)	4 (28.6)	3 (60.0)		0 (0)	1 (100.0)	63 (33.3)
SSA + CC	33 (25.8)	6 (18.2)	0 (0)		5 (71.4)	0 (0)	0 (0)	44 (23.3)
CC	24 (18.8)		4 (28.6)	0 (0)	1 (14.3)	0 (0)	0 (0)	29 (15.3)
SSA		16 (48.5)	5 (35.7)	0 (0)	0 (0)	1 (100.0)	0 (0)	22 (11.6)
TT	12 (9.4)	7 (21.2)		2 (40.0)	0 (0)	0 (0)	0 (0)	21 (11.1)
SSA + IF	3 (2.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (1.6)
IF	2 (1.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.1)
TT + CC	1 (0.8)	0 (0)	1 (7.1)	0 (0)	0 (0)		0 (0)	2 (1.1)
SSA + TT + CC	1 (0.8)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	2 (1.1)
SSA + CC + IF	1 (0.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.5)

SSA: Somatostatin analogues; CC: Cytotoxic chemotherapy; TT: Targeted therapy; IF: Interferon.